NWBO 10Q Shows UK Manufacturing Active US Node Nearing Selection Eden IND Complete
NWBO’s June 30 2025 10Q outlines clear steps toward launch readiness in both the UK and US. In the UK Advent BioServices in Sawston is already manufacturing DCVax-L under MHRA’s Specials and IFR frameworks with facility upgrades underway to expand capacity.
In the US the company is in final selection for a domestic assembly node with lyophilization aseptic filling cryogenic staging and co-packaging capabilities which are functions consistent with public information on Merck’s WP50 facility. Eden automation has completed the manufacturing section of the IND for DCVax-Direct indicating regulatory acceptance of its GMP-compliant closed-system process.
The filing highlights alignment with the UK’s SI 87 framework and the FDA’s CNPV program giving a pathway for rapid parallel rollout once approvals are in place. With roughly six weeks between the June 30 quarter end and the August 14 filing date there is room for further progress not yet reflected in the report.
Key near-term markers include UK treatment expansion pace public confirmation of the US node activation of the DCVax-Direct IND and regulatory milestones in both jurisdictions. The multi-node manufacturing network validated automation and established legal pathways described in the filing give a tangible basis for tracking next steps.
🚀 #DCVax$NWBO 10-Q: $MRK Winterfell 🏰 #Eden 🧬 UK–US Manufacturing Buildout and the Retail Storm to Come
Market Data 
Markets 
AI
